Video

Dr. Mannis Talks About Emerging Treatments for Acute Myeloid Leukemia

Author(s):

Gabriel Mannis, MD

In Partnership With:

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia.

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses new methods of treatment for acute myeloid leukemia (AML).

In the last 6 to 9 months, 4 new drugs have been approved by the FDA. CPX-351 (Vyxeos) was approved as a liposomal version of 7+3 chemotherapy, which combines cytarabine and daunorubicin in a 5:1 molar ratio. In patients with secondary AML, therapy-related AML, or de novo AML with myelodysplasia-related changes, the drug was shown to improve overall survival (OS). OS almost doubled for patients receiving CPX-351 relative to 7+3 chemotherapy.

For patients with secondary AML or therapy-related AML, CPX-351 is the new standard of care for fit patients who are able to undergo intensive chemotherapy. Opposed to traditional chemotherapy agents, patients do not lose their hair as it is much less toxic than standard 7+3 chemotherapy.

Related Videos
Jorge E. Cortes, MD
Nicolas Girard, MD
Sunil Adige, MD
Minoo Battiwalla, MD, MS
Samuel J. Klempner, MD
Jill Corre, PharmD, PhD
Chad Tang, MD
Grzegorz S. Nowakowski, MD, consultant, Division of Hematology, Department of Internal Medicine, enterprise deputy director, Clinical Research, professor, oncology, medicine, Mayo Clinic Comprehensive Cancer Center
Leo I. Gordon, MD
Terence W. Friedlander, MD
Related Content
Jorge Cortes, MD, of Georgia Cancer Center
October 21st 2024

New Global Hematology Journal Strives to Feature Innovative and Adaptable Research

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Shyam A. Patel, MD, PhD, University of Massachusetts Chan Medical School
October 16th 2024

Donor Clonal Hematopoiesis May Predict Post-Transplant Relapse and Outcomes in Hematologic Malignancies

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Ahmed Hamdy, MD, chief executive officer, Vincerx
October 11th 2024

VIP943 Generates Early Complete Responses, Is Safe in Advanced CD123+ Hematologic Malignancies

Armin Ghobadi, MD, of the Washington University School of Medicine
October 7th 2024

NT-I7 After CAR T-Cell Therapy Enhances CAR T Factors in R/R DLBCL